The role of the NY-ESO-1 in the prognosis of gastric cancer

Authors

  • Zvonimir Misir Department of Surgery, University Hospital Center “Sestre milosrdnice”, Zagreb, Croatia
  • Goran Glavčić Department of Surgery, University Hospital Center “Sestre milosrdnice”, Zagreb, Croatia https://orcid.org/0000-0002-2199-5938
  • Suzana Janković Department of Surgery, University Hospital Center “Sestre milosrdnice”, Zagreb, Croatia https://orcid.org/0000-0003-4103-5122
  • Ivan Kruljac Department of Clinical Research and Biostatistics, Poliklinika Solmed d.o.o., Zagreb, Croatia
  • Jakša Čugura Filipović Department of Surgery, University Hospital Center “Sestre milosrdnice”, Zagreb, Croatia
  • Kristina Čimić Department of Gynecology, General Hospital "Dr Ivo Pedišić", Sisak, Croatia https://orcid.org/0009-0001-6509-8358
  • Monika Ulamec Clinical Department of Pathology and Cytology “Ljudevit Jurak”, University Hospital Center “Sestre milosrdnice”, Zagreb, Croatia; Department of Pathology and Center of Excellence for Reproductive and Regenerative Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia

DOI:

https://doi.org/10.17305/bb.2023.9937

Keywords:

Gastric cancer (GC), survival, New York esophageal squamous cell carcinoma-1 (NY-ESO-1), metastases

Abstract

Gastric cancer (GC) is one of the most common malignancies worldwide and the fourth leading cause of cancer-related deaths. GC is a multifactorial disease influenced by both environmental and genetic factors. Its most critical features include invasiveness and high metastatic potential.Metastasis is a complex process, and our understanding of themechanisms involved remains incomplete. Growing evidence suggests that cancer-testis antigens (CTAs) play a crucial role in the metastatic potential of various tumors. Several studies have linked CTA expression with lower tumor differentiation, higher metastatic potential, and poor chemotherapy response. New York esophageal squamous cell carcinoma-1 (NY-ESO-1) antigen, part of the CTA group, is expressed in tumor tissues, while its expression in normal tissues is restricted to spermatogonia. This study aimed to determine the expression of NY-ESO-1 in primary adenocarcinoma of the stomach, both with and without metastasis in regional lymph nodes, and to compare it with TNM stage, age, gender, and survival. We analyzed GC tissue from 53 node-negative and 55 node-positive primary gastric carcinoma patients for NY-ESO-1 expression using immunohistochemical assay. The results were correlated with clinicopathological parameters and survival. Patients with positive NY-ESO-1 expression in primary tumors had a median survival of 19.0 months (range 14.1–24.0), in contrast to those with negative expression, who had a median survival of 52.0 months (range 0.0–133.3) (chi-square 7.99, P=0.005). T status, N status, and NY-ESO-1 expression were all independently associated with shorter survival. No significant difference in NY-ESO-1 expression in primary tumors was observed concerning lymph node metastasis status. In summary, our findings suggest that increased expression of NY-ESO-1 could potentially serve as a prognostic biomarker for GC.

Downloads

Download data is not yet available.
The role of the NY-ESO-1 in the prognosis of gastric cancer

Downloads

Published

28-12-2023

Issue

Section

Pathology

Categories

How to Cite

1.
The role of the NY-ESO-1 in the prognosis of gastric cancer. Biomol Biomed [Internet]. 2023 Dec. 28 [cited 2024 Apr. 13];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/9937